1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Guangzhou Jet Bio-Filtration Co. Ltd. Class A

Guangzhou Jet Bio-Filtration Co. Ltd. Class A

SSSE:688026
23.11
CNY
-0.28
(-1.20%)
0.31EPS
52.08P/E
2.21BMarket Cap
Oct 31Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.18
1.55
1.75
2.09
1.71
2.1
2.35
3.68
6.1
4.38
3.33
4.06
4.09
4.26
Basic EPS, GAAP
0.23
0.14
0.23
0.44
0.41
0.54
0.63
0.87
1.22
0.63
0.25
0.55
0.35
0.3
Free Cash Flow per Basic Share
-0.32
-0.2
- -
0.4
0.35
0.19
0.06
-0.46
-0.41
-0.05
-0.35
-0.41
0.49
- -
Dividend per Share
0.02
0.08
0.05
0.03
0.01
0.13
- -
0.37
0.09
0.43
0.08
0.09
0.1
-0.01
Book Value per Share
1.38
1.52
2.01
2.46
3.12
4.43
3.32
5.69
6.94
8.12
8.24
8.39
8.67
8.52
Tangible Book Value per Share
1.15
1.29
1.78
2.24
2.9
4.23
3.19
5.6
6.85
7.69
7.86
8.02
8.29
8.1
Basic Weighted Avg Shares
60
57
59
59
97
99
105
137
140
139
139
138
138
138
Sales/Revenue/Turnover
70
88
103
124
167
207
247
504
856
610
463
559
564
588
Operating Margin (%)
20.59
10.06
16.4
20.15
28.55
29.88
30.23
35.92
30.75
17.16
12.18
22.18
19.31
18.17
Depreciation Expense
3
5
8
9
10
10
12
22
52
62
65
61
54
- -
Net Income, GAAP
14
8
13
26
40
53
66
119
171
88
35
76
48
42
Effective Tax Rate (%)
12.28
16.55
19.17
14.82
14.51
13.86
13.39
19.21
12.52
10.52
8.41
20.08
19.43
17.08
Profit Margin (%)
19.36
9.23
13.07
21.22
24.16
25.47
26.73
23.69
20
14.38
7.51
13.54
8.55
7.09
Working Capital
-11
5
17
30
71
151
177
454
426
728
668
678
702
689
LT Debt
- -
30
19
- -
- -
- -
- -
9
30
315
337
360
383
394
Total Equity
82
90
119
147
186
282
348
797
972
1,140
1,158
1,185
1,225
1,208
Return on Invested Capital (%)
- -
4.02
7.23
12.53
20.39
21.96
20.87
20.63
20.19
6.95
2.45
5.02
3.17
2.75
Return on Capital (%)
- -
8.66
10.95
17.14
23.4
22.66
21
20.63
18.92
8.03
3.86
6.3
4.44
4.07
Return on Common Equity (%)
- -
9.46
12.82
19.77
24.29
22.58
21
20.85
19.35
8.31
3.03
6.48
4.03
3.47

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
6
1
LT Borrowings
382
388
394
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
140
140
140
Market Capitalization
2,261
2,305
2,205

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
810
786
792
Cash, Cash Equivalents & STI
398
466
456
Accounts Receivable, Net
136
108
125
Inventories
134
148
161
Total Current Liabilities
108
96
102
Payables & Accruals
- -
- -
- -
ST Debt
4
6
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.02%
9.31%
3.39%
Free Cash Flow
-6,492.88%
59.62%
-219.39%
Net Income, GAAP
30.13%
3.1%
-36.23%
Sales/Revenue/Turnover
24.11%
7.72%
0.95%
Total Cash Common Dividend
- -
52.09%
18.72%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
98
138
155
168
559
2025
124
144
- -
166
564
2026
108
170
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.16
0.15
0.16
0.55
2025
0.12
0.22
- -
-0.07
0.35
2026
-0.03
0.18
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.06
0.01
0.09
2025
- -
- -
- -
-0.01
0.1
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ye Yuan
Full Time Employees
1,490
Sector
Health technology
Industry
Medical specialties
Address
No.1 Doutang Road Guangzhou GD China 511356
IPO Date
Jan 22, 2020
Website
jetbiofil.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Guangzhou Jet Bio-Filtration Co., Ltd. (688026.SS) researches, develops, manufactures, and sells laboratory consumables and related products for biological research, biomedicine, molecular diagnostics, and cell therapy applications. The company offers a comprehensive portfolio including bioprocess consumables such as vacuum bottle filters with membrane pore sizes of 0.10 μm, 0.22 μm, and 0.45 μm in materials like MCE, Nylon, PVDF, CA, SFCA, and PES; cell culture products comprising flasks (T12.5 to T300 with plug seal, vent, or non-treated/TC-treated surfaces), dishes (35mm to 150mm), and plates (single to 384-well with flat or U-shaped bottoms); liquid handling items like serological pipettes, centrifuge tubes, and micro pipettors (JetPip™ Plus series, multi-channel, and micro volume); filtration products; molecular biology reagents; ProGro™ biological reagents; CellFac® multi-layer cell culture systems (1 to 40 layers); medical consumables such as petri dishes, ELISA plates, immuno micro plates, inoculating loops, cuvettes, and powder-free gloves; laboratory instruments including desktop high-speed microcentrifuges; high-performance membrane materials; and customization services. Founded in 2001 and headquartered in Huangpu District, Guangzhou, China, with over 160,000 square meters of floor space including 65,000 square meters of GMP cleanrooms and 40,000 square meters of smart manufacturing workshops, the company operates in more than 70 countries and regions, supported by subsidiaries in Hong Kong, the United States, Germany, and domestic entities like Guangzhou Jet General Clinic Co., Ltd., Guangzhou Jet Testing Technology Service Co., Ltd., Guangzhou Jet Packaging Materials Co., Ltd., and Guangzhou Biofil Air Purification Materials Co., Ltd. Recent developments include the opening of its European subsidiary JET Life Sciences GmbH in Wirges, Germany, on October 15, 2024, to expand global operations; the launch of a 30,000 square meter automated storage center in Zengcheng District and a 160,000 square meter new plant in Huangpu District in 2023-2024; a planned investment of 25 million yuan in July 2025 into the Guangzhou Zengcheng Nante Biomedical Investment Partnership fund to pursue industrial synergies and equity investments; the introduction of new products in September 2024 for cell culture, bioprocessing, and molecular biology; and achieving a Silver ranking in the EcoVadis Sustainability Assessment, ranking in the top 15% of enterprises.